+380.0%
CRWD vs GSK
+47.2%
+332.8%
-44.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.0% | 0.0% | -1.0% | -1.0% |
| 7D | -3.0% | -3.5% | +0.5% | -3.3% |
| 30D | -6.8% | -3.4% | -3.3% | -7.1% |
| 3M | +19.6% | -8.1% | +27.7% | +18.9% |
| 6M | +87.1% | -11.1% | +98.2% | +86.1% |
| YTD | +76.4% | +0.7% | +75.7% | +74.1% |
| 1Y | +90.8% | +20.1% | +70.7% | +86.4% |
| 3Y | +380.0% | +46.1% | +333.9% | +366.6% |
| All | +380.0% | +47.2% | +332.8% | +366.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling